EGFR Exon 20 NSCLC – October 2020 EGFR Exon 20 NSCLC – October 2020 Updated data from Phase 1/2 study of TAK-788 in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations reported 18 Sep 2020 […]
EGFR Exon 20 NSCLC – October 2020 EGFR Exon 20 NSCLC – October 2020 Rain Therapeutics presents positive results for RAIN-701 study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other […]
EGFR Exon 20 NSCLC – October 2020 EGFR Exon 20 NSCLC – October 2020 Preclinical data of DS-2087b in an NSCLC patient-derived xenograft (PDX) model with EGFR ins.ASV demonstrated antitumor effects 17 Sep 2020 DS-2087b (Selective inhibitor of EGFR/HER2 exon […]
EGFR Exon 20 NSCLC – October 2020 EGFR Exon 20 NSCLC – October 2020 Positive interim data from Phase 1/2a study of CLN-081 in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations reported 17 Sep […]
